Custo-efetividade de medicamentos biológicos no tratamento da psoríase em placas moderada a grave [Cost-effectiveness of biological drugs in moderate to severe plaque psoriasis]
2021
- 894Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage894
- Views762
- Downloads132
Dataset Description
Trata-se do repositório de versões do modelo completo de análise de custo-efetividade de medicamentos biológicos no tratamento da psoríase em placas moderada a grave elaborado pelo Núcleo de Avaliação de Tecnologias em Saúde do Instituto Nacional de Cardiologia (NATS-INC) com o intuito de dar subsídio às discussões sobre incorporação de tratamentos no Sistema Único de Saúde (SUS) pela Comissão Nacional de Incorporação de Tecnologia no SUS (Conitec). [This is the repository of versions of the complete model of cost-effectiveness analysis of biological drugs in the treatment of moderate to severe plaque psoriasis builded by the Center for the Evaluation of Health Technologies of the National Institute of Cardiology (NATS-INC) aiming to support the reimbursement discussions of the National Commission for Incorporating Technology into SUS (Conitec)] 24/08/2020 - Uma nova versão do modelo foi disponibilizada, considerando: - Revisão do número de doses do ustequinumabe - Novo preço propos...
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know